Advancing Nuclear Medicine

  • Serving 30.000 patients daily
  • 1 hour away from important European airport
  • Europe's most complete nuclear infrastructure

In a nutshell

#1

World leader in research and production of important ingredients for nuclear medicine.

Patiënts per day. This is the amount of people served with medicines from Petten.

1

Hour away from an important European airport. A strategic position for the distribution of nuclear medicine worldwide.

Our solutions

The starting material for technetium-99m (Tc-99m) generators. Tc-99m is perhaps the most important isotope in nuclear medicine. Doctors and hospitals use it to diagnose life-threatening diseases, such as cancer. Some 49 million nuclear drug investigations are conducted annually, and Tc-99m is used in more than 80% of these treatments.

The largest supplier of radioactive lutetium-177 worldwide. For the treatment of prostate cancer and neuroendocrine tumors.

The future of medical isotopes in diagnosis and treatment. Supports the development of new nuclear medicines within a unique nuclear infrastructure. Promises the delivery of promising medical services.

The largest area of ​​application of iridium-192 is gynecology, for example for the treatment of cervical cancer.

All products

Some of our success stories

In 2017, there was suddenly a worldwide shortage of iodine-125, used for brachytherapy for prostate cancer, because one of the large producers was temporarily shut down. McMaster & NRG joined forces for global supply.

Producing medical isotopes using only low enriched uranium? After a challenging design process, Curium and NRG are the first in Europe to produce molybdenum-99 with low enriched uranium. Recognizing the commitments made during the Nuclear Summit 2014, to phase out high enriched uranium (HEU) based medical isotopes.

A complex project has been brought to a successful conclusion: the development and installation of a production process for xenon-133 gas.

CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds

FIELD-LAB header

FIELD-LAB: an innovative partnership for the development of nucleair medicine!

FIELD-LAB is a partnership that aims to convert knowledge into new medical solutions. The aim is to accelerate the process from development to the production of nuclear therapies for cancer patients.

 

  • Supply of radiochemical solutions and radiofarmaceuticals to laboratories
  • Both research and GMP grade
  • Creation of radiochemical processes using innovative isotopes
  • Collaboration between academic and industrial partners
  • Portal to a fast-growing network with an open innovation culture
FIELD-LAB

Partners & clients around the world

Curium
Idb Holland
Pallas
BTG 1995 Horiz
IRE
ITM
1579291063176
Logo Erasmusmc
Logo Futurechemistry 1
Nki Avl Logo
Radboudumc Logo Eng

Advancing Nuclear Medicine

NRG Advancing Nuclear Medicine cares for the well-being of people worldwide. Especially for their health. We wish people to live longer, be more vital and feel happier. We believe everybody should have access to advanced treatments. New highly targeted treatments will cause less side effects and improve the quality of life.

We provide solutions to advance nuclear medicine ranging from complete irradiation services for medical isotope production, to access to R&D resources & commercial processing.

About

Publications

26 October 2020

For the past few months, pharmacist Jeske Hendriksen has been working as a PhD student in the Antoni van Leeuwenhoek hospital, where she is conducting research into radioactive cisplatin in the CISSPECT project. In this project, she is working alongside technical physician Else Aalbersberg, who has been at the Antoni van Leeuwenhoek for 8 years and involved in the CISSPECT project since the start.

24 March 2020

Thanks to intensive collaboration between Curium and NRG, a complex project has been brought to a successful conclusion: the development and installation of a production process for the medical isotope Xenon-133.

Publications